DK0539803T3 - Triazaspirodecanon-methyl-chromaner til bekæmpelse af sygdomme i centralnervesystemet - Google Patents

Triazaspirodecanon-methyl-chromaner til bekæmpelse af sygdomme i centralnervesystemet

Info

Publication number
DK0539803T3
DK0539803T3 DK92117606T DK92117606T DK0539803T3 DK 0539803 T3 DK0539803 T3 DK 0539803T3 DK 92117606 T DK92117606 T DK 92117606T DK 92117606 T DK92117606 T DK 92117606T DK 0539803 T3 DK0539803 T3 DK 0539803T3
Authority
DK
Denmark
Prior art keywords
nervous system
central nervous
methyl
triazaspirodecanone
chromanes
Prior art date
Application number
DK92117606T
Other languages
Danish (da)
English (en)
Inventor
Hans-Georg Dr Heine
Thomas Dr Glaser
Vry Jean Marie Viktor Dr De
Rudolf Dr Schohe-Loop
Wolfgang Dr Dompert
Henning Dr Sommermeyer
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of DK0539803T3 publication Critical patent/DK0539803T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK92117606T 1991-10-28 1992-10-15 Triazaspirodecanon-methyl-chromaner til bekæmpelse af sygdomme i centralnervesystemet DK0539803T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4135473A DE4135473A1 (de) 1991-10-28 1991-10-28 Triazaspirodecanon-methylchromane

Publications (1)

Publication Number Publication Date
DK0539803T3 true DK0539803T3 (da) 1999-08-30

Family

ID=6443565

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92117606T DK0539803T3 (da) 1991-10-28 1992-10-15 Triazaspirodecanon-methyl-chromaner til bekæmpelse af sygdomme i centralnervesystemet

Country Status (19)

Country Link
US (1) US6060482A (https=)
EP (1) EP0539803B1 (https=)
JP (1) JP3257708B2 (https=)
KR (1) KR930007945A (https=)
AT (1) ATE175414T1 (https=)
AU (1) AU650792B2 (https=)
CA (1) CA2081256A1 (https=)
CZ (1) CZ322492A3 (https=)
DE (2) DE4135473A1 (https=)
DK (1) DK0539803T3 (https=)
ES (1) ES2125879T3 (https=)
FI (1) FI924848A7 (https=)
GR (1) GR3029450T3 (https=)
HU (1) HUT64068A (https=)
IL (1) IL103546A0 (https=)
MX (1) MX9205869A (https=)
NO (1) NO923974L (https=)
TW (1) TW208010B (https=)
ZA (1) ZA928290B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19522088A1 (de) * 1995-06-19 1997-01-02 Bayer Ag Benzisothiazolyl-substituierte Aminomethylchromane
CA2226058C (en) * 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives
US6686370B2 (en) * 1999-12-06 2004-02-03 Euro-Celtique S.A. Triazospiro compounds having nociceptin receptor affinity
JPWO2003040382A1 (ja) * 2001-11-09 2005-03-03 株式会社カネカ 光学活性クロマン誘導体の製造法および中間体
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
NZ538307A (en) * 2002-09-09 2008-04-30 Janssen Pharmaceutica Nv Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
CA2542626A1 (en) * 2003-10-16 2005-04-21 William R. Collier Fluid level detector and alarm apparatus
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
CN103202840B (zh) * 2006-11-28 2015-02-11 詹森药业有限公司 3-(3-氨基-2-(r)-羟基-丙基)-1-(4-氟-苯基)-8-(8-甲基-萘-1-基甲基)-1,3,8-三氮杂-螺[4.5]癸烷-4-酮的盐
JP5490677B2 (ja) * 2007-04-09 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不安及び鬱病の処置のためのｏｒｌ−１受容体リガンドとしての１，３，８−三置換−１，３，８−トリアザ−スピロ［４．５］デカン−４−オン誘導体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826835A (en) * 1971-01-08 1974-07-30 Ciba Geigy Corp 8-benzofurylmethyl-1,3,8-triazaspiro(4,5)decanes as neuroleptics
US4826848A (en) * 1985-04-15 1989-05-02 Janssen Pharmaceutica N.V. Antidepressive substituted N-[(4-piperidinyl)alkyl] bicyclic condensed oxazol- and thiazolamines
US4689330A (en) * 1985-04-15 1987-08-25 Janssen Pharmaceutica N.V. Antidepressive substituted N-[(4-piperidinyl)alkyl] bicyclic condensed oxazol- and thiazolamines
US4749702A (en) * 1985-04-15 1988-06-07 Janssen Pharmaceutica N. V. Antidepressive substituted N-[(4-piperidinyl)alkyl] bicyclic condensed oxazol- and thiazolamines
US4957928A (en) * 1986-06-26 1990-09-18 Ciba-Geigy Corporation Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE3831888A1 (de) * 1988-09-20 1990-03-29 Troponwerke Gmbh & Co Kg Arzneimittel zur behandlung von apoplexia cerebri
DE4039631A1 (de) * 1990-12-12 1992-06-17 Troponwerke Gmbh & Co Kg Neuroprotektive kombination

Also Published As

Publication number Publication date
AU2626592A (en) 1993-04-29
KR930007945A (ko) 1993-05-20
CZ322492A3 (en) 1993-07-14
ES2125879T3 (es) 1999-03-16
MX9205869A (es) 1993-04-01
NO923974L (no) 1993-04-29
EP0539803A1 (de) 1993-05-05
EP0539803B1 (de) 1999-01-07
HUT64068A (en) 1993-11-29
GR3029450T3 (en) 1999-05-28
ATE175414T1 (de) 1999-01-15
TW208010B (https=) 1993-06-21
DE59209607D1 (de) 1999-02-18
FI924848A7 (fi) 1993-04-29
JPH05222040A (ja) 1993-08-31
IL103546A0 (en) 1993-03-15
HU9203382D0 (en) 1993-01-28
FI924848A0 (fi) 1992-10-26
DE4135473A1 (de) 1993-04-29
US6060482A (en) 2000-05-09
ZA928290B (en) 1993-05-04
CA2081256A1 (en) 1993-04-29
JP3257708B2 (ja) 2002-02-18
AU650792B2 (en) 1994-06-30
NO923974D0 (no) 1992-10-13

Similar Documents

Publication Publication Date Title
DK0612322T3 (da) Fremgangsmåde til adskillelse af 5-methyl-tetrahydrofolsyre
DK0539803T3 (da) Triazaspirodecanon-methyl-chromaner til bekæmpelse af sygdomme i centralnervesystemet
ATE244215T1 (de) Flüssigkristalline verbindungen
NO941958L (no) Fremstilling av substituerte piperidiner
MX9200977A (es) Proceso para producir l-lisina por fermentacion.
NO904576L (no) Aminopyridinylaminofenol og beslektede forbindelser, mellomprodukter, fremgangsmaate for deres fremstilling og anvendelse som medikamenter.
ES2002663A6 (es) Procedimiento para la preparacion de diazaoxaespirodecanos sustituidos como estabilizadores para polimeros
AU1554992A (en) Novel cyclic aminophenylacetic acid derivative, production thereof, and immune response modulator containing the same as active ingredient
ID24135A (id) Metode sintesa pirol amida
MX9207468A (es) Proceso para preparar acido 2,6-naftalenodicarboxilico purificado.
DK0667898T3 (da) Anvendelser af TAU/neurofilamentproteinkinasen PK40
DE3887102D1 (de) Substituierte Derivate von 20,21-Dinoreburnamenin, Verfahren zur Herstellung und so hergestellte Zwischenprodukte, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammenstellungen.
ES8305717A1 (es) Procedimiento para la obtencion de derivados de 2-amino-3,4-dihidropiridina sustituidos.
ATE44029T1 (de) Indolderivate, verfahren zu deren herstellung und deren anwendung.
AR241137A2 (es) "procedimiento para preparar beta-metilen-2 o 3-tiofenetanamina".
DK0547502T4 (da) Hærdeligt bindemiddel og fremgangsmåde til fremstilling deraf
DK0521766T3 (da) Hidtil ukendt fremgangsmåde til syntese af enantiomerer af 3-aminochromanderivater
PT746556E (pt) Compostos triciclicos com afinidade para o receptor 5-ht1a
ATE15671T1 (de) M-4- und isom-4-derivate, ihre herstellung und diese enthaltende zusammensetzungen.
DE69109953D1 (de) Alfa-fluorocarbonsäurederivate als Zwischenprodukte zur Herstellung von Fungiziden.
EP0260605A3 (en) Dihydropyridine-5-phosphonic acid cyclic ester
DK0478941T3 (da) Lægemidler indeholdende substituerede 2-cyclohexen-1-yl-amin-derivater og deres anvendelse til bekæmpelse af sygdomme
FI880063A7 (fi) Nya derivat av 4,4-dimetyl tetrahydropyr-2-on, foerfarande foer deras framstaellning och deras anvaendning vid syntes av pyretinoidfoereningar.
DE3577183D1 (de) Verwendung eines diamins zur herstellung eines erythrozyten-weichmachers.
FI892731L (fi) Foerfarande foer framstaellning av nya antiallergiska medel.